Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC

Journal of Thoracic Oncology

Volumn 8, Issue 3, 2013, Pages 301-308

  Guo, Chengcheng ^a,b   Shao, Ruping ^a   Correa, Arlene M ^a   Behrens, Carmen ^a   Johnson, Faye M ^a   Raso, Maria G ^a   Prudkin, Ludmila ^a   Solis, Luisa M ^a   Nunez, Maria I ^a   Fang, Bingliang ^a   Roth, Jack A ^a   Wistuba, Ignacio I ^a   Swisher, Stephen G ^a   Lin, Tongyu ^b   Pataer, Apar ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Biomarker; EphA2; Lung cancer; PKR

Indexed keywords

ANTIBODY; EPHRIN RECEPTOR A2; PROTEIN KINASE; TUMOR MARKER;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; STAINING; TISSUE MICROARRAY;

EID: 84874114930     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318282def7     Document Type: Article

References (41)

1. Brower V. Biomarker studies abound for early detection of lung cancer. J Natl Cancer Inst 2009;101: 11-13.
2. Greenberg AK, Lee MS. Biomarkers for lung cancer: clinical uses. Curr Opin Pulm Med 2007;13: 249-255.
3. Balachandran S, Kim CN, Yeh WC, Mak TW, Bhalla K, Barber GN. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J 1998; 17: 6888-6902.
4. Barber GN. The dsRNA-dependent protein kinase, PKR and cell death. Cell Death Differ 2005;12: 563-570.
5. Gil J, Alcamí J, Esteban M. Induction of apoptosis by double-stranded- RNA-dependent protein kinase (PKR) involves the alpha subunit of eukaryotic translation initiation factor 2 and NF-kappaB. Mol Cell Biol 1999;19: 4653-4663.
6. Williams BR. Signal integration via PKR. Sci STKE 2001;89: re2.
7. Barber GN. Host defense, viruses and apoptosis. Cell Death Differ 2001;8: 113-126.
8. Pataer A, Hu W, Xiaolin L, et al. Adenoviral endoplasmic reticulum-targeted mda-7/interleukin-24 vector enhances human cancer cell killing. Mol Cancer Ther 2008;7: 2528-2535.
9. Pataer A, Vorburger SA, Barber GN, et al. Adenoviral transfer of the melanoma differentiation-associated gene 7 (mda7) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR). Cancer Res 2002;62: 2239-2243.
10. von Holzen U, Bocangel D, Pataer A, et al. Role for the double-stranded RNA-activated protein kinase PKR in Ad-TNF-alpha gene therapy in esophageal cancer. Surgery 2005;138: 261-268.
11. Vorburger SA, Pataer A, Yoshida K, et al. Role for the double-stranded RNA activated protein kinase PKR in E2F-1-induced apoptosis. Oncogene 2002;21: 6278-6288.
12. Hii SI, Hardy L, Crough T, et al. Loss of PKR activity in chronic lymphocytic leukemia. Int J Cancer 2004;109: 329-335.
13. Li S, Koromilas AE. Dominant negative function by an alternatively spliced form of the interferon-inducible protein kinase PKR. J Biol Chem 2001;276: 13881-13890.
14. Beretta L, Gabbay M, Berger R, Hanash SM, Sonenberg N. Expression of the protein kinase PKR in modulated by IRF-1 and is reduced in 5qassociated leukemias. Oncogene 1996;12: 1593-1596.
15. Haines GK 3rd, Becker S, Ghadge G, Kies M, Pelzer H, Radosevich JA. Expression of the double-stranded RNA-dependent protein kinase (p68) in squamous cell carcinoma of the head and neck region. Arch Otolaryngol Head Neck Surg 1993;119: 1142-1147.
16. Singh C, Haines GK, Talamonti MS, Radosevich JA. Expression of p68 in human colon cancer. Tumour Biol 1995;16: 281-289.
17. Pataer A, Raso MG, Correa AM, et al. Prognostic significance of RNAdependent protein kinase on non-small cell lung cancer patients. Clin Cancer Res 2010;16: 5522-5528.
18. He Y, Correa AM, Raso MG, et al. The role of PKR/eIF2α signaling pathway in prognosis of non-small cell lung cancer. PLoS ONE 2011;6:e24855.
19. Ireton RC, Chen J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets 2005;5: 149-157.
20. Miyazaki T, Kato H, Fukuchi M, Nakajima M, Kuwano H. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer 2003;103: 657-663.
21. Brannan JM, Dong W, Prudkin L, et al. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 2009;15: 4423-4430.
22. Kinch MS, Moore MB, Harpole DH Jr. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 2003;9: 613-618.
23. Brannan JM, Sen B, Saigal B, et al. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila) 2009;2: 1039-1049.
24. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010;10: 165-180.
25. Ito T, Jagus R, May WS. Interleukin 3 stimulates protein synthesis by regulating double-stranded RNA-dependent protein kinase. Proc Natl Acad Sci USA 1994;91: 7455-7459.
26. Larsen AB, Stockhausen MT, Poulsen HS. Cell adhesion and EGFR activation regulate EphA2 expression in cancer. Cell Signal 2010;22: 636-644.
27. Saelens X, Kalai M, Vandenabeele P. Translation inhibition in apoptosis: caspase-dependent PKR activation and eIF2-alpha phosphorylation. J Biol Chem 2001;276: 41620-41628.
28. Jagus R, Joshi B, Barber GN. PKR, apoptosis and cancer. Int J Biochem Cell Biol 1999;31: 123-138.
29. Mankouri J, Dallas ML, Hughes ME, et al. Suppression of a pro-apoptotic K+ channel as a mechanism for hepatitis C virus persistence. Proc Natl Acad Sci USA 2009;106: 15903-15908.
30. Hu W, Hofstetter W, Wei X, et al. Double-stranded RNA-dependent protein kinase-dependent apoptosis induction by a novel small compound. J Pharmacol Exp Ther 2009;328: 866-872.
31. Qian W, Liu J, Tong Y, et al. Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin- 24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia 2008;22: 361-369.
32. Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 2004;15: 419-433.
33. Ishikawa M, Miyahara R, Sonobe M, et al. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma. Lung Cancer 2012;76: 431-438.
34. Faoro L, Singleton PA, Cervantes GM, et al. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem 2010;285: 18575-18585.
35. Jackson D, Gooya J, Mao S, et al. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res 2008;68: 9367-9374.
36. Lee JW, Stone RL, Lee SJ, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res 2010;16: 2562-2570.
37. Wykosky J, Gibo DM, Debinski W. A novel, potent, and specific ephrinA1- based cytotoxin against EphA2 receptor expressing tumor cells. Mol Cancer Ther 2007;6(12 Pt 1): 3208-3218.
38. Miao H, Wei BR, Peehl DM, et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol 2001;3: 527-530.
39. Macrae M, Neve RM, Rodriguez-Viciana P, et al. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 2005;8: 111-118.
40. Smith KD, Mezhir JJ, Bickenbach K, et al. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol 2006;80: 1110-1120.
41. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64: 7099-7109.